StockNews.AI
CLGN
StockNews.AI
97 days

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

1. CollPlant Biotechnologies (CLGN) will release Q1 financial results on May 28, 2025. 2. The company focuses on regenerative and aesthetic medicine using non-animal-derived rhCollagen. 3. CLGN entered a commercialization agreement with Allergan for dermal fillers in 2021. 4. The products target tissue repair and organ manufacturing using proprietary technology.

Earnings
+5.81%Current Return
VS
+0.47%S&P 500
$1.5505/14 07:08 AM EDTEvent Start
$1.6405/15 02:04 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial report could signal positive growth for CLGN, similar to historical performance spikes after earnings releases. Strategic partnerships with industry leaders like Allergan strengthen CLGN's position in the market.

How important is it?

The announcement of financial results and strategic partnerships raises confidence in the company's future, likely attracting investor interest.

Why Long Term?

The innovation in regenerative medicine and continued partnerships are likely to drive sustained interest and growth in market valuation over the long term.

Related Companies

ABBV
, /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg SOURCE CollPlant WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News